Curcuma longa Polypharmaceutical Composition for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies often rely on multiple treatment modalities that face challenges with drug resistance and recurrence due to the molecular heterogeneity of tumors, and cocktails of drugs often have limited synergy and adverse effects.
Innovation Solution
Development of poly-pharmaceutical drugs comprising bioactive compounds from Curcuma longa, specifically combining high, medium, and low polarity extracts in optimized ratios to achieve synergistic action against cancer cells, enhancing T-cell infiltration and immunotherapy efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple drug molecules are combined in a cocktail to address molecular heterogeneity, then the ability to target diverse biochemical species is improved, but the number of unique molecules is limited due to adverse effects from molecular interactions
Solution Approach 1:
The invention segments the complex mixture of plant metabolites into distinct polarity-based fractions (high, medium, and low polarity compounds). Each fraction contains specific subsets of bioactive compounds that work synergistically without the harmful interactions that occur in uncontrolled multi-drug cocktails. This segmentation allows targeted delivery of complementary compounds while avoiding adverse molecular interactions.
Solution Approach 2:
The invention creates a composite pharmaceutical composition by combining multiple polarity fractions of plant-derived metabolites in specific ratios. This composite approach leverages the synergistic effects of diverse compounds (polyphenols, terpenoids, peptides, polysaccharides, proteins) while the natural compatibility of plant-derived compounds avoids the harmful interactions seen in synthetic drug cocktails.
2Adaptability or versatility
If drug cocktails are artificially combined to treat cancer, then multiple molecular targets are addressed, but true synergy in pharmacological activity is lacking leading to drug resistance and recurrence
Solution Approach 1:
The invention merges multiple polarity fractions containing different classes of bioactive compounds into a unified polypharmaceutical composition. The high polarity fraction (peptides, polysaccharides, proteins), medium polarity fraction (polyphenols, curcuminoids), and low polarity fraction (terpenoids) work together in a coordinated manner to produce true synergistic effects that overcome cancer cell adaptive responses and prevent drug resistance.
Solution Approach 2:
The invention optimizes the composition by adjusting the ratios of different polarity fractions based on their complementary pharmacological activities. This parameter optimization ensures that the combined composition achieves synergistic effects greater than the sum of individual components, providing durable clinical responses free from resistance and recurrence.
3Ease of operation
If a single-agent drug is used to address multiple molecular events, then treatment simplicity is improved, but the ability to modulate diverse biochemical responses is insufficient
Solution Approach 1:
The invention creates a multi-functional pharmaceutical composition where a single polypharmaceutical product delivers multiple classes of bioactive compounds simultaneously. This unified composition can modulate diverse biochemical responses across multiple molecular targets while maintaining treatment simplicity, as the entire synergistic mixture is administered as one agent rather than multiple separate drugs.
Data Source
AI summary
Disclosed are compositions and methods for treating or ameliorating the symptoms of cancer (e.g., oral cancer) by using a poly-pharmaceutical drug, whose composition consists of relationally optimized ratios of bioactive compounds to enhance their pharmacological characteristics.